ArticleClinical kidney journal2026
Intratubular light chain amyloidosis: a comprehensive analysis of disease spectrum and clinicopathological characteristics.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The disease spectrum of intratubular light chain amyloidosis (AL) remains unknown. Methods: Patients with intratubular AL from a single center were retrospectively analyzed and stratified into three groups: Group 1, complicated by extra-tubular AL; Group 2, complicated by light chain cast nephropathy (LCCN); and Group 3, isolated intratubular AL. Clinical features, pathological findings, treatment regimens, and renal prognosis were compared across the groups. Results: The cohort (126 patients) was predominantly male (65.1%), with a mean age of 57 years and a high prevalence of the λ-light chain (78.6%). Group 1 was characterized by the lowest serum creatinine (Scr) and albumin, but the highest urinary protein and prevalence of systemic AL (all Conclusion: Intratubular AL is frequently identified in patients with renal AL and LCCN, presenting with characteristics associated with these two disorders. Isolated intratubular AL could progress to MM or systemic AL, thereby necessitating vigilant clinical monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.